[PDF] Top 20 15.-Evaluacion Para Los Aprendizajes y La Enseñanza

... Hence drugs which induce this enzyme e.g. rifampicin, phenytoin, ritonavir etc. will decrease the plasma level of canagliflozin. Therefore, its dose has to be increased to 300 mg/day when used in combination with ... See full document

... 2 diabetes continues to be a challenging disease to ...adequate diabetes control. Canagliflozin, the first sodium-glucose cotransporter 2 inhibitor presently available on the market, offers a unique ... See full document

... 2 diabetes is a disease affecting metabolic disorders characterized by chronic ...2 diabetes (T2DM) is resulting from either resistance to insulin action, inadequate insulin secretion, excessive or ... See full document

... As described above, several studies in- vestigated long-term metabolic effects of treatment with VPA. In general, no changes were reported with respect to fasting serum insulin and C-peptide in VPA-treated ... See full document

... proliferation[37]. In addition to that, there may be reduction in the adverse effects of both drugs by decreasing the maximum dose[38]. Metformin also decrease the risk of pancreatitis that associated with the use of ... See full document

... of canagliflozin in βCF. Inspection of the canagliflozin homeostasis model assess- ment beta (HOMA-beta) data seems to indicate that canagliflozin compared to placebo results in increased values of ... See full document

... Exclusion criteria included those who had castrated for treatment on cancer testis or prostate, taking any medications known to affect sex hormone level (e.g, antiandrogenic agents for prostate cancer) and those ... See full document

... Receptors always play a prominent role in physiology and pathology of various disease conditions in humans as well as in animals. Due to interdependency and complexity of receptors in their mechanism, one can't ... See full document

... 2 diabetes mellitus receiv- ing high doses of insulin: a randomized ...of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insu- lin therapy +/- oral agents ... See full document

... The novel group of secretagogues which acts on both insulin and glucagon secretion are these DPP-4 inhibitors, together with GLP-1 receptor ...of diabetes and its complications are ... See full document

... 2 diabetes mellitus and treated them with 100 mg canagliflozin once a day, as a monotherapy or as add-on/combination therapy with existing antidiabetic treatment between May 2016 and December ... See full document

... 2 diabetes patients with hypertension at general in a 500 bed tertiary care teaching ...of treatment, the Amlodipine and Telmisartan group no significant difference in SBP (131mmHg and ...of ... See full document

... The treatment of older patients with T2DM must take into consideration factors specific to these patients, in- cluding the increased prevalence of comorbidities and use of concomitant medications, with patient ... See full document

... the novel findings of the HPS, it seems likely that lipid man- agement guidelines will be modified to suggest that people with diabetes who would have qualified for the HPS (> 40 years of age with total ... See full document

... after treatment with DPP-4 ...2 diabetes mellitus patients were analysed for variations in levels of exocrine pancreatic enzymes after use of dipeptidyl peptidase (DPP) 4 ...under treatment ... See full document

... Lukens,6 Forsham, 7 and others pointed out some time ago that multiple injections of regular insulin before meals, perhaps accompanied by one or more injections of lo[r] ... See full document

... conventional diabetes treatment on the de- velopment and progression of early microvascular com- plications of type 1 diabetes ...intensive treatment regimen was designed to achieve glycemic ... See full document

... 2 diabetes mellitus (NIDDM) have shown significant absorption of Glimepiride within 1 hour after administration and peak drug levels (C max ) at 2 to 3 ... See full document

... No Treatment groups largely ...No Treatment group and 11/56 (20%) ...No Treatment group (0% vs 33% p = ...’ treatment is ...Early treatment may have both benefits and ... See full document

... with canagliflozin compared with placebo, with incidence of serious AEs low across treatment ...the canagliflozin groups (2.6%) discontinued treatment due to AEs, compared with two subjects ... See full document